These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 10482466)

  • 1. 7-Chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoyl-amino)benzoyl ]-2,3,4,5-tetrahydro-1H-1-benzazepine (OPC-41061): a potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist.
    Kondo K; Ogawa H; Yamashita H; Miyamoto H; Tanaka M; Nakaya K; Kitano K; Yamamura Y; Nakamura S; Onogawa T; Mori T; Tominaga M
    Bioorg Med Chem; 1999 Aug; 7(8):1743-54. PubMed ID: 10482466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vasopressin and a nonpeptide antidiuretic hormone receptor antagonist (OPC-31260).
    Burrell LM; Phillips PA; Stephenson JM; Risvanis J; Johnston CI
    Blood Press; 1994 Mar; 3(1-2):137-41. PubMed ID: 8199714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel design of nonpeptide AVP V(2) receptor agonists: structural requirements for an agonist having 1-(4-aminobenzoyl)-2,3,4, 5-tetrahydro-1H-1-benzazepine as a template.
    Kondo K; Ogawa H; Shinohara T; Kurimura M; Tanada Y; Kan K; Yamashita H; Nakamura S; Hirano T; Yamamura Y; Mori T; Tominaga M; Itai A
    J Med Chem; 2000 Nov; 43(23):4388-97. PubMed ID: 11087564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonpeptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 4'-[5-(substituted methylidene)-2,3,4,5-tetrahydro-1H-1-ben zoazepine-1-carbonyl]benzanilide and 4'-[5-(substituted methyl)-2,3-dihydro-1H-1-benzoazepine-1- carbonyl]benzanilide derivatives.
    Matsuhisa A; Kikuchi K; Sakamoto K; Yatsu T; Tanaka A
    Chem Pharm Bull (Tokyo); 1999 Mar; 47(3):329-39. PubMed ID: 10212383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.
    Yamamura Y; Nakamura S; Itoh S; Hirano T; Onogawa T; Yamashita T; Yamada Y; Tsujimae K; Aoyama M; Kotosai K; Ogawa H; Yamashita H; Kondo K; Tominaga M; Tsujimoto G; Mori T
    J Pharmacol Exp Ther; 1998 Dec; 287(3):860-7. PubMed ID: 9864265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist.
    Yamamura Y; Ogawa H; Yamashita H; Chihara T; Miyamoto H; Nakamura S; Onogawa T; Yamashita T; Hosokawa T; Mori T
    Br J Pharmacol; 1992 Apr; 105(4):787-91. PubMed ID: 1387020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetamide derivatives as novel arginine vasopressin V(2) receptor agonists.
    Tsukamoto I; Koshio H; Akamatsu S; Kuramochi T; Saitoh C; Yatsu T; Yanai-Inamura H; Kitada C; Yamamoto E; Sakamoto S; Tsukamoto S
    Bioorg Med Chem; 2008 Nov; 16(21):9524-35. PubMed ID: 18835174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Orally active, nonpeptide vasopressin V2 receptor antagonists: a novel series of 1-[4-(benzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepines and related compounds.
    Ogawa H; Yamashita H; Kondo K; Yamamura Y; Miyamoto H; Kan K; Kitano K; Tanaka M; Nakaya K; Nakamura S; Mori T; Tominaga M; Yabuuchi Y
    J Med Chem; 1996 Aug; 39(18):3547-55. PubMed ID: 8784453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonpeptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 2-phenyl-4'-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]benzanil ide derivatives.
    Matsuhisa A; Tanaka A; Kikuchi K; Shimada Y; Yatsu T; Yanagisawa I
    Chem Pharm Bull (Tokyo); 1997 Nov; 45(11):1870-4. PubMed ID: 9396163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of an orally active vasopressin V1 receptor antagonist.
    Burrell LM; Phillips PA; Stephenson J; Risvanis J; Hutchins AM; Johnston CI
    Clin Exp Pharmacol Physiol; 1993 May; 20(5):388-91. PubMed ID: 8391950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antidiuretic effects of a novel nonpeptide vasopressin V(2)-receptor agonist, OPC-51803, administered orally to dogs.
    Nakamura S; Hirano T; Onogawa T; Itoh S; Hashimoto A; Yamamura Y; Kondo K; Mori T; Kambe T
    J Pharmacol Sci; 2004 Apr; 94(4):426-33. PubMed ID: 15107583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands.
    Serradeil-Le Gal C; Wagnon J; Valette G; Garcia G; Pascal M; Maffrand JP; Le Fur G
    Prog Brain Res; 2002; 139():197-210. PubMed ID: 12436936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological characterization of YM087, a potent, nonpeptide human vasopressin V1A and V2 receptor antagonist.
    Tahara A; Saito M; Sugimoto T; Tomura Y; Wada K; Kusayama T; Tsukada J; Ishii N; Yatsu T; Uchida W; Tanaka A
    Naunyn Schmiedebergs Arch Pharmacol; 1998 Jan; 357(1):63-9. PubMed ID: 9459574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological profile of VP-343, a novel selective vasopressin V2 receptor antagonist, in rats.
    Naito A; Ohtake Y; Hasegaw H; Fukaya AY; Kurasawa T; Naito K; Matsukawa H; Oguma T; Ezure Y; Tsuriya Y; Tanaka H; Koike K; Shigenobu K
    Biol Pharm Bull; 2000 Feb; 23(2):182-9. PubMed ID: 10706381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist.
    Serradeil-Le Gal C; Lacour C; Valette G; Garcia G; Foulon L; Galindo G; Bankir L; Pouzet B; Guillon G; Barberis C; Chicot D; Jard S; Vilain P; Garcia C; Marty E; Raufaste D; Brossard G; Nisato D; Maffrand JP; Le Fur G
    J Clin Invest; 1996 Dec; 98(12):2729-38. PubMed ID: 8981918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of a novel non-peptide vasopressin V1 receptor antagonist (OPC-21268) in the rat.
    Burrell LM; Phillips PA; Stephenson J; Risvanis J; Hutchins AM; Johnston CI
    J Endocrinol; 1993 Aug; 138(2):259-66. PubMed ID: 8228734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antidiuretic effects of a nonpeptide vasopressin V(2)-receptor agonist, OPC-51803, administered orally to rats.
    Nakamura S; Hirano T; Tsujimae K; Aoyama M; Kondo K; Yamamura Y; Mori T; Tominaga M
    J Pharmacol Exp Ther; 2000 Dec; 295(3):1005-11. PubMed ID: 11082435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of YM218, a nonpeptide vasopressin V1A receptor-selective antagonist, on human vasopressin and oxytocin receptors.
    Tahara A; Tsukada J; Tomura Y; Kusayama T; Wada K; Ishii N; Taniguchi N; Suzuki T; Yatsu T; Uchida W; Shibasaki M
    Pharmacol Res; 2005 Mar; 51(3):275-81. PubMed ID: 15661579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. (+/-)-3-[4'-(N,N-dimethylamino)cinnamyl]benzazepine analogs: novel dopamine D1 receptor antagonists.
    Shah JH; Kline RH; Geter-Douglass B; Izenwasser S; Witkin JM; Newman AH
    J Med Chem; 1996 Aug; 39(17):3423-8. PubMed ID: 8765528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and structure-activity relationships of amide derivatives of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetic acid as selective arginine vasopressin V2 receptor agonists.
    Tsukamoto I; Koshio H; Kuramochi T; Saitoh C; Yanai-Inamura H; Kitada-Nozawa C; Yamamoto E; Yatsu T; Shimada Y; Sakamoto S; Tsukamoto S
    Bioorg Med Chem; 2009 Apr; 17(8):3130-41. PubMed ID: 19321349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.